(Hypertension. 2001;37:148.)
© 2001 American Heart Association, Inc.
Scientific Contributions |
From the Whitaker Cardiovascular Institute and Department of Biochemistry, Boston University School of Medicine, Boston, Mass.
Correspondence to Peter Brecher, PhD, Boston University School of Medicine, 715 Albany St, Boston, MA 02118. E-mail pbrecher{at}bu.edu
AbstractThe anti-inflammatory
effects of salicylate are well known, but the intracellular mechanisms
underlying those effects remain to be clarified and are not explained
solely by an influence on cyclooxygenase activity.
In the present study, we have used cardiac fibroblasts stimulated
by either angiotensin II (Ang II) or platelet-derived
growth factor (PDGF) to demonstrate an inhibitory effect of
salicylate on the phosphorylation of the nonreceptor
tyrosine kinases, proline-rich tyrosine kinase 2 (PYK2) and c-Src, by
immunoprecipitation and immunoblotting methods. This
inhibition was dose dependent, with a clear effect observed at
concentrations between 5 and 20 mmol/L salicylate. Intracellular
Ca2+ chelation and protein kinase C (PKC) inhibition
reduced Ang II and PDGF-induced PYK2 and c-Src
phosphorylation. Salicylate significantly inhibited the
phosphorylation of both of the tyrosine kinases
activated by either ionophore A23187 or thapsigargin treatment,
which led to an elevation of cytosolic Ca2+. Activation of
PKC by phorbol ester phosphorylated both PYK2 and Src,
and this effect also was attenuated by salicylate. In contrast,
salicylate had no effect on either the transactivation of the epidermal
growth factor receptor by Ang II or the phosphorylation
of phospholipase C-
by PDGF. These studies indicate a novel site of
action for salicylate on PYK2 and c-Src phosphorylation
and suggest that this inhibitory effect on these important
signaling intermediates may be through a Ca2+- and
PKC-dependent mechanism.
Key Words: NSAIDs kinase signal transduction fibroblasts
This article has been cited by other articles:
![]() |
Z. Ying, F. R.C. Giachini, R. C. Tostes, and R. C. Webb Salicylates dilate blood vessels through inhibiting PYK2-mediated RhoA/Rho-kinase activation Cardiovasc Res, July 1, 2009; 83(1): 155 - 162. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Florio, S. Casagrande, F. Diana, A. Bajetto, C. Porcile, G. Zona, S. Thellung, S. Arena, A. Pattarozzi, A. Corsaro, et al. Chemokine Stromal Cell-Derived Factor 1{alpha} Induces Proliferation and Growth Hormone Release in GH4C1 Rat Pituitary Adenoma Cell Line through Multiple Intracellular Signals Mol. Pharmacol., February 1, 2006; 69(2): 539 - 546. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Sekimoto, J. Eipper-Mains, S. Pond-Tor, and C. M. Boney {alpha}v{beta}3 Integrins and Pyk2 Mediate Insulin-Like Growth Factor I Activation of Src and Mitogen-Activated Protein Kinase in 3T3-L1 Cells Mol. Endocrinol., July 1, 2005; 19(7): 1859 - 1867. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Sadoshima Novel AT1 Receptor-Independent Functions of Losartan Circ. Res., April 19, 2002; 90(7): 754 - 756. [Full Text] [PDF] |
||||
![]() |
K. L. Byron and P. A. Lucchesi Signal Transduction of Physiological Concentrations of Vasopressin in A7r5 Vascular Smooth Muscle Cells. A ROLE FOR PYK2 AND TYROSINE PHOSPHORYLATION OF K+ CHANNELS IN THE STIMULATION OF Ca2+ SPIKING J. Biol. Chem., February 22, 2002; 277(9): 7298 - 7307. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Perez-G., M. Melo, A. D. Keegan, and J. Zamorano Aspirin and Salicylates Inhibit the IL-4- and IL-13-Induced Activation of STAT6 J. Immunol., February 1, 2002; 168(3): 1428 - 1434. [Abstract] [Full Text] [PDF] |
||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2001 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |